How Is Passive Targeting Used in Clinical Applications?
Passive targeting is currently being explored in a variety of clinical applications, particularly in the treatment of cancer. Several nanomedicines that utilize passive targeting are already approved by regulatory bodies and are being used in clinical settings. For instance, Doxil, a liposomal formulation of the chemotherapy drug doxorubicin, exploits passive targeting to deliver the drug more effectively to tumor tissues.
